Table 2.

Mean cGFR at month 12 and mean change in cGFR from baseline to month 12

Belatacept (n = 84)CNI (n = 89)
BaselineMonth 12Mean Change from BaselineBaselineMonth 12Mean Change from Baseline
Mean cGFR, ml/min per 1.73 m2 (SD)53.5 (11.01)60.5 (16.19)7.0 (11.99)a54.5 (10.26)56.5 (14.42)2.1 (10.34)a
Baseline cGFR
    <45 (n = 40)40.2 (3.87)43.9 (10.56)3.7 (11.01)41.1 (3.35)43.9 (7.43)2.8 (8.17)
    45 to 60 (n = 70)51.7 (3.98)61.7 (13.88)10.0 (13.41)51.4 (3.67)53.2 (12.84)1.9 (11.72)
    >60 (n = 59)66.2 (4.98)71.8 (11.38)5.7 (10.17)65.8 (4.20)67.8 (10.81)2.0 (10.13)
Baseline CNI
    CsA (n = 74)51.9 (10.11)59.2 (18.17)7.7 (14.51)53.1 (11.66)53.1 (16.18)0 (10.86)
    TAC (n = 95)54.8 (11.61)61.5 (14.59)6.4 (9.70)55.6 (8.98)59.2 (12.41)3.7 (9.73)
Time from transplantation to randomization
    6 to 12 months (n = 48)54.2 (10.31)59.6 (16.24)5.4 (12.56)54.5 (8.43)56.1 (14.23)1.6 (11.80)
    12 to 18 months (n = 25)49.7 (10.27)53.8 (19.28)4.1 (13.57)53.3 (12.10)51.8 (16.05)−1.5 (11.41)
    >18 months (n = 85)53.8 (11.66)61.4 (15.02)7.6 (10.68)54.5 (10.93)57.1 (14.03)2.8 (9.49)
Diabetes status
    diabetic (n = 45)53.5 (13.27)55.5 (16.73)2.7 (11.17)54.6 (10.61)54.6 (17.60)−0.1 (12.64)
    nondiabetic (n = 124)53.5 (10.02)62.5 (15.66)8.8 (11.95)54.5 (10.22)57.1 (13.35)2.8 (9.51)
Type of transplant
    living donor (n = 83)54.9 (10.66)60.5 (14.07)5.9 (11.34)56.1 (10.43)57.5 (15.86)1.6 (11.58)
    deceased donor (n = 86)52.2 (11.29)60.5 (18.16)8.0 (12.62)52.9 (9.94)55.5 (12.97)2.6 (9.09)
  • The values are the mean changes in cGFR from baseline by patient subsets, ml/min per 1.73 m2 (SD). n for patient subsets may not add up to the overall population because of missing values or information. CsA, cyclosporine; TAC, tacrolimus.

  • a P = 0.0058 for difference between treatment groups in change from baseline (post-hoc analysis).